Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
Blood|June 19, 2004
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCRMatthias Ritgen, Stephan Stilgenbauer, Nils von Neuhoff, et al.
Blood|December 8, 2005
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphomaChristiane Pott, Carsten Schrader, Stefan Gesk, et al.
Transplantation|January 12, 2012
Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder RegistryHeiner Zimmermann, Ilske Oschlies, Susanne Fink, et al.
Blood|October 1, 2005
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaMonika Brüggemann, Thorsten Raff, Thomas Flohr, et al.
Blood|July 9, 2004
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study GroupGeorg Lenz, Martin Dreyling, Eva Schiegnitz, et al.
Oncoimmunology|March 5, 2016
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30Christian Kellner, Andreas Günther, Andreas Humpe, et al.
Genes, Chromosomes & Cancer|April 29, 2014
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasmsDarko Gosenca, Beate Kellert, Georgia Metzgeroth, et al.
European Journal of Haematology|November 19, 2016
Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trialOthman Al-Sawaf, Kirsten Fischer, Carmen D Herling, et al.
Cancers|October 14, 2022
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression AnalysisAnke Schilhabel, Peter Jonas Walter, Paula Cramer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2013
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1)Anne T Nies, Elke Schaeffeler, Heiko van der Kuip, et al.
Pageof 10